Cesca Therapeutics (NASDAQ:KOOL) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp., is headquartered in Rancho Cordova, California. “
Separately, ValuEngine upgraded Cesca Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th.
NASDAQ:KOOL opened at $0.38 on Thursday. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.93 and a quick ratio of 0.97. Cesca Therapeutics has a 1-year low of $0.22 and a 1-year high of $4.14. The firm has a market capitalization of $6.96 million, a P/E ratio of -0.39 and a beta of -0.96.
Cesca Therapeutics (NASDAQ:KOOL) last released its quarterly earnings results on Monday, August 13th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.16. Cesca Therapeutics had a negative return on equity of 18.05% and a negative net margin of 322.75%. The business had revenue of $2.00 million during the quarter, compared to analyst estimates of $3.00 million. Research analysts expect that Cesca Therapeutics will post 0.1 EPS for the current fiscal year.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
See Also: Leveraged Buyout (LBO) Explained
Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.